Merck & Co., Inc. Increase (Decrease) in Operating Capital
Merck & Co., Inc. (MRK) reported Increase (Decrease) in Operating Capital of $1.19 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingCapital · last filed 2026-08-07
- Merck & Co., Inc. increase (decrease) in operating capital for the quarter ending 2026-06-30 was -$423.00M, a 118.73% decline year-over-year.
- Merck & Co., Inc. increase (decrease) in operating capital for the quarter ending 2026-03-31 was $1.61B, a 56.55% decline year-over-year.
- Merck & Co., Inc. increase (decrease) in operating capital for the quarter ending 2025-09-30 was -$1.31B.
- Merck & Co., Inc. increase (decrease) in operating capital for the quarter ending 2025-06-30 was $2.26B, a 123.22% increase year-over-year.
| Period end | Increase (Decrease) in Operating Capital 3 month | Increase (Decrease) in Operating Capital 3 month as first filed | Increase (Decrease) in Operating Capital 6 month | Increase (Decrease) in Operating Capital 6 month as first filed | Increase (Decrease) in Operating Capital 9 month | Increase (Decrease) in Operating Capital 9 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$423.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.19B 10-Q · filed 2026-08-07 | ||||
| 2026-03-31 | $1.61B 10-Q · filed 2026-05-04 | |||||
| 2025-09-30 | -$1.31B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $945.00M derived: sum of 2 quarters · filed 2026-08-07 | $4.66B 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $2.26B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $5.97B 10-Q · filed 2026-08-07 | ||||
| 2025-03-31 | $3.71B 10-Q · filed 2026-05-04 | |||||
| 2024-09-30 | -$2.58B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.57B derived: sum of 2 quarters · filed 2025-11-05 | $1.81B 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $1.01B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $4.39B 10-Q · filed 2025-08-05 | ||||
| 2024-03-31 | $3.38B 10-Q · filed 2025-05-02 | |||||
| 2023-09-30 | -$2.18B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$541.00M derived: sum of 2 quarters · filed 2024-11-06 | $2.35B 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $1.64B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $4.53B 10-Q · filed 2024-08-05 | ||||
| 2023-03-31 | $2.89B 10-Q · filed 2024-05-03 | |||||
| 2022-09-30 | -$263.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.14B derived: sum of 2 quarters · filed 2023-11-03 | $2.44B 10-Q · filed 2023-11-03 | |||
| 2022-06-30 | $1.40B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $2.70B 10-Q · filed 2023-08-07 | ||||
| 2022-03-31 | $1.30B 10-Q · filed 2023-05-05 | |||||
| 2021-09-30 | $139.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.60B derived: sum of 2 quarters · filed 2022-11-03 | $3.79B 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $1.46B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $3.65B 10-Q · filed 2022-08-05 | ||||
| 2021-03-31 | $2.19B 10-Q · filed 2022-05-05 | $2.10B 10-Q · filed 2021-05-05 | ||||
| 2020-09-30 | $1.37B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $1.82B derived: sum of 2 quarters · filed 2021-11-05 | $5.48B 10-Q · filed 2021-11-05 | $5.64B 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | $446.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $4.11B 10-Q · filed 2021-08-09 | $4.19B 10-Q · filed 2020-08-05 | |||
| 2020-03-31 | $3.67B 10-Q · filed 2021-05-05 | |||||
| 2019-09-30 | $91.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $534.00M derived: sum of 2 quarters · filed 2020-11-05 | $3.47B 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $443.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $3.38B 10-Q · filed 2020-08-05 | ||||
| 2019-03-31 | $2.94B 10-Q · filed 2020-05-06 | |||||
| 2018-09-30 | $760.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $561.00M derived: sum of 2 quarters · filed 2019-11-05 | $2.03B 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | -$199.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.27B 10-Q · filed 2019-08-06 | ||||
| 2018-03-31 | $1.47B 10-Q · filed 2019-05-08 | |||||
| 2017-09-30 | $2.92B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $2.72B derived: sum of 2 quarters · filed 2018-11-06 | $5.26B 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | -$198.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $2.34B 10-Q · filed 2018-08-07 | ||||
| 2017-03-31 | $2.54B 10-Q · filed 2018-05-08 | |||||
| 2016-09-30 | $564.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $2.13B derived: sum of 2 quarters · filed 2017-11-07 | $3.00B 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $1.56B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $2.44B 10-Q · filed 2017-08-08 | ||||
| 2016-03-31 | $875.00M 10-Q · filed 2017-05-09 | |||||
| 2015-09-30 | -$223.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $169.00M derived: sum of 2 quarters · filed 2016-11-07 | $787.00M 10-Q · filed 2016-11-07 | |||
| 2015-06-30 | $392.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $1.01B 10-Q · filed 2016-08-08 | ||||
| 2015-03-31 | $618.00M 10-Q · filed 2016-05-09 | |||||
| 2014-09-30 | -$2.07B derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$1.65B derived: sum of 2 quarters · filed 2015-11-05 | -$950.00M 10-Q · filed 2015-11-05 | |||
| 2014-06-30 | $415.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $1.12B 10-Q · filed 2015-08-06 | ||||
| 2014-03-31 | $703.00M 10-Q · filed 2015-05-07 | |||||
| 2013-09-30 | -$1.31B derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$679.00M derived: sum of 2 quarters · filed 2014-11-10 | $494.00M 10-Q · filed 2014-11-10 | |||
| 2013-06-30 | $636.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $1.81B 10-Q · filed 2014-08-07 | ||||
| 2013-03-31 | $1.17B 10-Q · filed 2014-05-08 | |||||
| 2012-09-30 | $282.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $867.00M derived: sum of 2 quarters · filed 2013-11-07 | $2.34B 10-Q · filed 2013-11-07 | |||
| 2012-06-30 | $585.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $2.06B 10-Q · filed 2013-08-07 | ||||
| 2012-03-31 | $1.47B 10-Q · filed 2013-05-09 | |||||
| 2011-09-30 | -$821.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$403.00M derived: sum of 2 quarters · filed 2012-11-09 | $664.00M 10-Q · filed 2012-11-09 | |||
| 2011-06-30 | $418.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $1.49B 10-Q · filed 2012-08-07 | ||||
| 2011-03-31 | $1.07B 10-Q · filed 2012-05-08 | |||||
| 2010-09-30 | -$787.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | -$1.84B derived: sum of 2 quarters · filed 2011-11-08 | -$782.00M 10-Q · filed 2011-11-08 | -$781.60M 10-Q · filed 2010-11-08 | ||
| 2010-06-30 | -$1.06B derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-08 | $5.00M 10-Q · filed 2011-08-08 | $5.50M 10-Q · filed 2010-08-06 | |||
| 2010-03-31 | $1.06B 10-Q · filed 2011-05-09 | |||||
| 2009-09-30 | $2.27B derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $5.19B 10-Q · filed 2010-11-08 | ||||
| 2009-06-30 | $2.92B 10-Q · filed 2010-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |